|
Palo Alto, CA, September 19, 2007 — Telik, Inc. (Nasdaq: TELK)
announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Wednesday, September 26, 2007 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). Telik’s presentation will be webcast live and will be available for replay through the Telik website, www.telik.com, through October 3, 2007.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA®, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA™, which is in clinical development for the treatment of myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2007 Press Releases2006
Press Releases
2005
Press ReleasesEvents |
